CMS Outlook Details Major Changes for Payers and Providers, Provides Suggestions to Accelerate Switch to Value-Based Models and Improve Equity
A report from the University of Pennsylvania’s Leonard Davis Institute of Health Economics discusses the coming changes aimed at reducing [...]
New CMS Innovation Appointment Could Affect Medicare Drug Pricing Policy
Elizabeth Fowler has been appointed director of the Center for Medicare and Medicaid Innovation (CMMI). Her previous roles will provide [...]
COVID-19 Data Dashboard Provides Clear Vaccine Information for People With Disabilities
Researchers, students, and patient advocates at Johns Hopkins have revealed a new data dashboard tool that provides information on COVID-19 [...]
New CMS Director Could Indicate Shift in Medicare Prescription Drug Pricing Policy
Arielle Woronoff is joining the new administration as director of the CMS Office of Legislation. She previously held worked in [...]
JAMA Article Proposes HTA As Solution for Out-of-Control Prescription Drug Prices; Speculation That Biden Will Look to ICER Model
In a recent article published in JAMA, the authors note that the US spends more per capita for prescription drugs [...]
ICER Unsatisfied With Fibrogen’s Roxadustat Evidence; FDA Calls Advisory Committee
ICER held a meeting on February 11th, during which its independent appraisal committee agreed that it was not possible to [...]
NIH Statement on Improving Equity; Francis Collins Announces UNITE Initiative to Address Structural Racism in Biomedical Science
Dr. John Denny, CEO of the NIH’s All of Us Research Program, released a statement on how the NIH is [...]
Sanofi Publishes 2021 Report on Principles in Prescription Drug Pricing, Notes $890 Million in Patient Assistance Programs
Unjustified price increases continue to be a point of contention in the pharma industry. Sanofi has published a report aimed [...]
Novartis and NHS England Agree on Price of Costly SMA Drug; Zolgensma Nearly £1.8 Million per Dose
SMA (spinal muscular atrophy) is characterized by muscle weakness, paralysis, and eventual loss of movement. It is associated with extremely [...]
MSL Society Offers Wednesday Webinar on Navigating KOL Engagements During COVID-19
The Medical Science Liaison Society (MSLS) will host a webinar this Wednesday from 12 PM – 1 PM CST on [...]
ICER Reveals Prescription Drug Cost Sharing Policies, Concludes Many Will Dislike Findings
A recent ICER whitepaper discusses a range of policies designed to limit drug prices. It focuses on three main topics [...]
GOP Avoids Drug Cost Questions During Becerra HHS Hearings
Xavier Becerra is Biden’s pick for HHS (Health and Human Services). Earlier this week, he took questions from Republican lawmakers, [...]
Aetion’s Take on RWE Expansion in Europe
Aetion’s Ashley Jaska, Vice President of Science, and Nicholas Deltour, Vice President of Real-World Solutions, offered their insight into how [...]
Storage a Major Challenge in Genomics Tools for Precision Medicine
Genomics tools are driving progress in precision medicine. These tools, such as next generation sequencing (NGS) technologies, allow for large [...]
Prescription Drugs Only One Piece of High Healthcare Costs–Look to Provider Cost
Dr. Anupam Jena, an associate professor of healthcare policy at Harvard Medical School and doctor at Massachusetts General Hospital, shares [...]
California and New York Newest States Seeking to Create Their Own Contracts With Medicaid
A growing number of states have decided to form their own contracts with Medicaid. Most recently, California and New York [...]
ISMPP Releases Results of Poll on Marketing Scenario
The ISMPP recently published the results of a poll asking respondents how they might respond to a scenario where a [...]
2021 Healthcare Predictions As Democrats Hold House, Senate, Presidential Office
Now that Democrats hold control of the House of Representatives, the Senate, and Biden has been elected president, healthcare is [...]
Register Today for Virtual ISPOR 2021 Conference on HEOR, HTAs, and RWD
ISPOR will host its yearly conference on HEOR (health economics and outcomes research) virtually, from May 17-20. The theme of [...]
A Conversation with Gilead Leader on Impact of RWE in Drug Development
Dr. Diana Brainard, Senior Vice President and Virology Therapeutic Area Head at Gilead Sciences, provides her thoughts on the role [...]
Understanding the Spectrum of Low-Value Care and Economic Implications
In a recent study, researchers compared over one thousand low-value care recommendations from five US healthcare organizations (USPSTF, ACP, ACC/AHA, [...]
The Case for Prescription Drug Price Transparency: Listen to Patients and Providers
Although recent regulations require healthcare systems to provide pricing information, there is no standardized method to do so. With these [...]
The US FDA Has a Different Rubric for Cancer Drug Approval Than the UK and Canada
Different regulatory bodies have different criteria when it comes to drug approval, especially in the case of cancer drugs. The [...]
Sarepta’s New Treatment for Duchenne Muscular Dystrophy Approved by FDA, $1 Million Yearly Cost Despite Lack of Confirmation Studies
Sarepta Therapeutics has created a third drug for use in Duchenne Muscular Dystrophy (DMD), termed Amondys 45. It recently received [...]
How Will Emphasis on Patient Centricity and ICER Influence Payer Decisions?
The 21st Century Cures Act, as well as FDA guidelines, are putting a spotlight on patient centricity—from drug development to [...]